Skip to main content
. Author manuscript; available in PMC: 2025 Apr 1.
Published in final edited form as: Lung Cancer. 2024 Feb 24;190:107510. doi: 10.1016/j.lungcan.2024.107510

Table 2.

Prognostic impact of KRAS and comutations by PD-L1 level

PD-L1 0% (n=651) PD-L1 1–49% (n=603) PD-L1 ≥50% (n=743)
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
HR for OS, KRASm vs wt1 1.46 1.18- 0.001 1.25 0.98- 0.068 0.96 0.78- 0.675
HR for rwPFS, KRASm vs wt1 1.23 1.01- 0.035 1.11 0.90- 0.342 0.99 0.83- 0.944
Adjusted pairwise comparisons for OS1
 Single KRASm vs KRASwt 1.15 0.87- 0.322 1.12 0.84- 0.456 0.95 0.76- 0.613
 KRASm/STKUm vs KRASwt/STK11wt 1.81 1.37- <0.001 2.32 1.65- <0.001 1.38 0.89- 0.145
  KRASm/STK11m vs single KRASm 1.57 1.14- 0.006 2.08 1.46- <0.001 1.46 0.94- 0.092
 KRASm/KEAP1m vs KRASwt/KEAP1wt 2.37 1.74- <0.001 2.15 1.46- <0.001 1.34 0.90- 0.143
  KRASm/KEAP1m vs single KRASm 2.03 1.45- <0.001 1.77 1.20- 0.004 1.54 1.04- 0.032
 Triple KRASm/STK11m/KEAP1m vs single KRASm 2.73 1.75- <0.001 2.64 1.62- <0.001 2.35 1.25- 0.008
  Triple mut vs KRASm/STK11m 2.01 1.24- 0.005 1.37 0.78- 0.271 2.29 0.97- 0.060
  Triple mut vs KRASm/KEAP1m 1.67 0.86- 0.130 2.11 0.92- 0.080 1.72 0.81- 0.157
1

All HR adjusted for treatment type, demographics (sex, race, age), year of diagnosis, histology, smoking status, ECOG performance status, practice type.

HR, hazard ratio; OS, overall survival; rwPFS, real world progression-free survival; m, mutant; wt, wild type